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Summary 
We examined liver specimens from 24 patients with uveal melanoma (UM), including 15 
patients who had succumbed to their disseminated disease. We found two distinct 
growth patterns of UM metastasis: infiltrative (n=12) and nodular (n=3). In the infiltrative 
pattern, individual UM cells with a CD133+ cancer stem cell-like phenotype were 
present and formed aggregates of Stage I <50µm diameter micrometastases in the 
sinusoidal spaces. These micrometastases appeared to expand, destroy adjacent 
hepatocytes and form Stage II 51-500µm diameter and then Stage III >500µm diameter 
metastases, which were encapsulated by collagenized fibrous septae. In the nodular 
growth pattern, CD133+ melanoma cells aggregated adjacent to portal venules, and 
subsequently appeared to grow and efface the adjacent hepatocytes to form Stage II 
51-500µm diameter nodules that surrounded the portal venule. These avascular 
nodules appeared to further expand to form Stage III >500µm diameter nodules that 
exhibited vascularization with minimal fibrosis. The tumor stem cell-like phenotype seen 
in individual UM cells was lost as the tumors progressed. There were CD56+ natural 
killer (NK) cells in sinusoidal spaces and CD3+ lymphocytes in periportal areas. The 
nodular growth pattern showed UM cells expressing MMP9 and VEGF.  UM cells in 
both above-described growth patterns exhibited variable BAP1 expression.  We 
propose that changes in the liver microenvironment are related to metastatic UM 
growth. These include immune regulation within the sinusoidal space for the infiltrative 
pattern and changes in the VEGF:PEDF ratio for the nodular pattern. 
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1.0 Introduction 
Uveal melanoma (UM) is the most common primary intraocular malignancy in 
adults with an annual incidence of 6-7 cases/1,000,000 in the Caucasian population.1 
Approximately 40% of UM metastasize to the liver within 10 years of diagnosis of the 
primary intraocular tumor2, and when UM metastasizes, the liver is typically the initial 
site of metastasis in 95% of cases.3 The life expectancy of patients with metastatic UM 
is only 4 to 6 months1, and at present there are no highly effective treatments for these 
metastases.4 
 The Zimmerman hypothesis, which was formulated in the late 1970s, proposed 
that enucleation of the eye for UM potentiated hematogenous spread of the tumor and a 
2-year post-enucleated risk of death.5 This theory was subsequently disproven, 
particularly when investigators calculated primary and metastastic UM doubling times.  
Their extrapolation demonstrated that small, clinically undetectable UM 
micrometastases were present in the liver, even at the time of diagnosis of the primary 
intraocular tumor in patients who ultimately succumbed from hepatic metastasis.6 Our 
laboratory corroborated those results when we found small hepatic UM 
micrometastases in liver specimens obtained post-mortem from patients who died from 
metastastic UM.8 
 In our prior study8, we found three Stages of metastases: Stage I: <50µm 
diameter micrometastases within the sinusoidal space; Stage II: 51-500µm diameter 
metastases that formed expanded collections of cells within the sinusoidal space; and 
Stage III: >500µm diameter collections of cells that formed two patterns. We 
characterized the two Stage III patterns as the ‘lobular’ and ‘portal’ patterns.8 The 
lobular pattern appeared to be an expansion of Stage I to III intra-sinusoidal growth,  
which infiltrated the portal lobule and was surrounded by fibrous septae. In contrast, the 
portal pattern appeared to efface, rather than infiltrate, the surrounding liver; we 
hypothesized that the portal pattern arose in the perivascular area of the portal triad.8  
 In this study, we examined liver specimens from an additional 24 cases, including  
15 UM patients who had died from metastatic disease. We examined for the growth 
stages and growth patterns as previously described8 and explored mechanisms that 
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may account for these growth patterns. Based on our findings, we propose the term 
“infiltrative” for the lobular pattern and nodular” for the portal pattern. 
 
2.0 Materials and Methods 
 This study was approved by the Emory University School of Medicine Institutional 
Review Board, Atlanta, Georgia. Sections of livers obtained post-mortem from patients 
who had UM were obtained from the Department of Molecular and Clinical Cancer 
Medicine, Royal Liverpool and Broadgreen University, Liverpool, UK (CM, SEC) and the 
Department of Ophthalmology, University of Copenhagen, Copenhagen, Denmark (SH). 
The patients’ samples had been pseudoanonymized for data other than age, sex, and 
cause of death. For each case, sections of the livers including an area of suspected 
metastasis found during autopsy were obtained. The sections were fixed in 10% neutral 
buffered formalin, routinely processed, and 4-µm sections were obtained by a 
microtome and placed on slides. The sections measured from 2.0cm X0.9 cm to 3.4cm 
X2.6cm. Sections from each case were stained with hematoxylin and eosin (H&E) and 
Masson trichrome (MT).  
Immunohistochemical (IHC) staining using the avidin-biotin complex technique 
(Dako, Carpinteria, CA) was used to stain other sections from each case for HMB45 
(1:50), BAP1 (C-4, Santa Cruz, Insight Biotechnology Ltd,. Middlesex, UK, 1µg/ml-1), 
CD3 (Leica Microsystems, Bannockburn, IL, prediluted), CD20 (Leica Microsystems, 
prediluted) and CD31 (Dako,1:180). A red chromogen (Vector Red) was used for 
HMB45 and BAP1, and a brown chromogen (DAB) was used for CD3, CD20 and CD31. 
For immunofluorescence (IF) staining, sections of the livers were blocked in normal goat 
serum (5%) in PBS, followed by incubation with primary antibody. After washing, 
sections were incubated with appropriate fluorescent-conjugated secondary antibody, 
counterstained with 4',6-diamidino-2-phenylindole (DAPI, Vector Laboratories), and 
mounted (Vector Laboratories).  IF staining for each case was performed for CD56 
(R&D Systems, Minneapolis, MN), CD 133 (Biorbyt, San Francisco, CA), HMB45 
(ABCAM, Cambridge, MA), MMP9 (Cell Signaling Technology, Boston, MA), VEGF 
(AMCAM) and a dual label HMB45/CD133. IF was examined by confocal microscopy 
(Nikon CI R1, Tokyo, Japan).  The H&E, MT and IHC stained slides were examined by 
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light microscopy to determine the presence and distribution of Stage I, Stage I and 
Stage III metastases as previously described.8 The number of these three stages of 
metastases was determined for each section in triplicate (40X, Olympus BHTU, Tokyo, 
Japan) and the averages of these numbers was used as the count of Stage I, Stage II 
and Stage III metastases per section which was normalized to number of metastases 
per cm2. The presence or absence of nuclear or cytoplasmic IHC and IF staining for 
each antibody or dual-labelled section was recorded. For CD31, the presence and 
location of endothelial cells staining was recorded. 
 
3.0 Results 
 We examined autopsy liver sections from 24 UM patients, including 13 men and 
11 women. The average age at the time of death was 55 years, with a range from 23 to 
75 years. Of the 24 cases, 9 patients died of causes other than metastatic UM. Liver 
sections of those 9 patients did not contain metastatic UM. Examination of liver sections 
of all of the remaining 15 patients who died from metastatic UM showed metastastic 
disease at various stages.8 The predominant growth pattern, including all three stages 
in 12 patients, was infiltrative and the predominant growth pattern in the remaining 3 
patients was nodular.  In the livers showing an infiltrative UM growth pattern the number 
of metastases in order of decreasing frequency was Stage I >> Stage II > Stage III; 
whereas there were much fewer Stage I, II and III UM metastases in livers that exhibited 
the nodular pattern as shown in Figure 1.  
IHC stains for BAP1 were positive in 6 of 12 infiltrative pattern and 1 of 3 nodular 
pattern metastases. The BAP1 staining was positive both in the nucleus and cytoplasm. 
Many that exhibited positive BAP1 staining also contained aggregates of tumor cells 
that were negative for BAP1. IF stains were also positive for CD56 in NK cells in the 
sinusoidal space and IHC stains for CD3 for T cells in the periportal area (Figure 2).  
The histopathologic, IHC and IF results in both growth patterns are summarized in 
Table 1. 
The infiltrative growth pattern exhibited melanoma growth within the sinusoidal 
space. All 12 cases of predominantly infiltrative growth pattern contained individual 
melanoma cells within the sinusoidal space (Figure 3), which demonstrated positive 
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immunostaining for HMB45. Dual labeling showed that many of the individual HMB45 
melanoma cells within the sinusoidal space also labeled for CD133. All cases exhibited 
Stage I HMB45 positive islands of micrometastatic UM that measured up to 50µm in 
diameter (Figure 4). These cases also contained Stage II metastases (Figure 5), which 
appeared as expansions of Stage I UM; the micrometastases had formed 51-500µm 
diameter aggregates, with disappearance of the adjacent hepatocytes. These UM 
metastases expressed MMP9 but not VEGF. There were occasional Stage III 
metastases (Figure 6), which measured greater than 500µm in diameter, and were 
composed of larger expansions of melanoma cells that were now surrounded by fibrous 
septae demonstrated with a trichrome stain. The Stage III metastases failed to express 
MMP9 or VEGF.  All three stages of the infiltrative growth pattern did not contain CD31+ 
vascular channels within the tumor, although there were CD31 vascular channels 
present in the surrounding fibrous septae. Rare individual HMB45/CD133 melanoma 
cells appeared to decrease in number as the stages progressed. 
The nodular growth pattern predominantly contained nodules of tumor that 
effaced, rather than infiltrated, the adjacent hepatocytes. In this growth pattern, 
individual melanoma cells, which expressed an HMB45/CD133 tumor stem cell-like 
phenotype were present in portal venules within the portal triad as well as the periportal 
area (Figure 7). There were CD3+ lymphocytes present in this area. Stage II 
metastases (Figure 8) were composed of nodules of tumor that appeared as 
expansions of tumor within the fibrovascular septae of the portal triad. Tumor nodules 
were adjacent to and/or surrounded the portal venule and effaced the surrounding 
hepatocytes. These nodules expressed MMP9 and VEGF. Stage III nodular growth 
pattern tumor (Figure 9) contained CD31+ vascular channels, exhibited MMP9 and 
VEGF expression and the vascular channels were within the nodule and at its 
advancing edge.   
 
4.0 Discussion 
Whilst significant progress has been made in our understanding of primary UM 
over the last decade, there are only a few studies on human metastatic UM to the liver, 
due to the relative difficulty in accessing this material, since many UM patients do not 
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undergo laparoscopic staging or abdominal surgery. Some recent studies (including our 
own), however, have undertaken morphological, immunohistochemical and genetic 
analyses of metastatic UM.8-14    
Our laboratory has previously described the progression of metastatic UM to the 
liver in 10 patients who succumbed to the tumor to exhibit three histologic stages and 
two growth patterns, lobular and portal.8 In the current study of an additional 24 cases 
including 15 patients who died from metastatic UM to the liver, we expanded our 
findings. We chose to use the term infiltrative rather than lobular and nodular rather than 
portal growth patterns, as we feel that the new terms better describe the pathologic 
findings as well as correspond to the biologic processes. 
 Current evidence suggests that primary UM undergoes a series of mutational 
events that allow it to develop and metastasize. Somatic GNAQ or GNA11 mutations 
initiate the melanocytic neoplastic proliferation leading to nevi and UM in 85% of 
cases.12 Metastasis predictors in UM include clinical factors (tumor size, ciliary body 
involvement, extraocular spread); histological features (epithelioid cytomorphology, 
mitotic count, closed laminin loops); and genetic findings (chromosome 3 loss, 
chromosome 8q gain, BAP1 deletion, class 2 gene expression profile, and lack of 
SF3B1 and EIF1AX mutations).15-19 It is not known in which sequence later genetic 
alterations occur, which aberrations contribute to the malignant phenotype, which ones 
enable metastasis, and whether any explain why metastases almost always involve the 
liver. That being said, it is clear that many metastatic UM cases demonstrate 
chromosome 3 loss, polysomy 8q, and have BAP1 inactivating mutations. Indeed, BAP1 
immunostaining of metastatic UM showed that BAP1 expression was absent in 77% 
cases in one study.9 Our finding in this study of variable BAP1 expression in hepatic 
metastases of UM in both infiltrative and nodular tumors, including variable expression 
within a given liver section, supports the concept that although BAP1 mutations are 
important for promoting UM metastasis, the BAP1 mutation may or may not be lost in 
the metastases in the liver. 
During the metastatic process in cancer, it is hypothesized that only a small 
percentage of cells (i.e. single clones) is released from a primary tumor, and ultimately 
one clone successfully forms distant colonies.20 These clones could be composed of 
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mature differentiated cells, or of immature stem cell-like neoplastic cells. The advantage 
of the latter is that they are less immunogenic, and thereby can avoid the immune 
surveillance system present in the blood and many organs, on dissemination. There is 
some evidence that metastatic UM cells exhibit cancer stem cell-like phenotypes.21-23  
Our findings of dual-labeled CD45/CD133 individual UM cells in the sinusoidal space, 
portal venule and periportal area provides further evidence of a cancer stem cell-like 
phenotype of UM, as a precursor to Stages I-III metastases. Many metastatic UM cells 
that survive in the liver appear to be ‘dormant’ and not proliferating.20 As we currently 
understand the process of metastatic UM to the liver, primary UM expressing high levels 
of c-Met and/or CXCR4 aggregate in the liver, which contains the c-Met ligand, HGF/SF 
and the CXCR4 ligand, SDF.24,25 Individual UM cells that have a CD133+ tumor stem 
cell-like phenotype appear to give rise to the infiltrative or nodular growth patterns, 
depending on whether the tumor is in the sinusoidal space or periportal area (Figure 
10). There may be stochastic properties related to the branching pattern of the 
sinusoidal space that are related to the ability of individual metastatic UM cells to 
aggregate and form micrometastases in the infiltrative growth pattern.8 The sinusoidal 
space contains resident NK cells, as demonstrated in this study, and boosting of these 
NK cells eliminates micrometastatic UM in the liver in an animal model.26 Other immune 
related cells in the sinusoidal microenvironment may change during tumor progression, 
including an M1 to M2 macrophage phenotypic shift.27   
Our previous work has indicated  that 0-50μm micrometastases receive their 
nutrition form blood in the sinusoidal space and larger infiltrative pattern metastases 
develop “pseudosinusoidal” spaces from stellate cells.8 This appears to obviate the 
need for angiogenesis in the infiltrative growth pattern. In this study, we observed tumor 
MMP9 expression in Stage II infiltrative tumors, which we hypothesize is due to tumor 
hypoxia. This MMP production allows the melanoma to dissect through tissue planes 
and stellate cell proliferation leads the creation of pseudosinusoidal spaces8, thus 
allowing tumor nutrition and oxygenation and obviating angiogenesis. Interestingly, we 
did not observe MMP9 expression in Stage III infiltrative melanoma. Alternatively, tumor 
cells may arise in the perivascular tissue of the portal triad8, and in this study we 
demonstrate a predominance of CD3+ T cells in that area. Although this periportal 
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space is not exposed to the NK cells in the sinusoidal space, there is experimental 
evidence that  proteins, such as PEDF secreted by hepatocytes, counteracts VEGF 
produced by melanoma cells and vascular endothelium, thus limiting tumor 
angiogenesis.28  Hypoxia results in increased  HIF1α and downstream  MMP and VEGF 
production.29 PEDF is degraded by MMP2 and MMP930; our study shows MMP9 and 
VEGF expression in Stages II and III nodular growth pattern melanoma, and supports 
the concept of MMP9 degradation of PEDF and a local change in the microenvironment 
favoring an increased VEGF:PEDF ratio with resultant tumor  angiogenesis. Our 
hypothesis of metastatic UM progression relative to the hepatic microenvironment is 
shown in Figure 11. 
Interestingly, other studies have shown growth patterns of metastatic colon 
cancer to the liver, which are similar to our study of metastatic UM.31,32 Those studies 
have shown a replacement pattern, which is very similar to the infiltrative pattern, the 
pushing pattern, which is very similar to the nodular pattern, and the desmoplastic 
pattern, which is similar to the Stage III infiltrative pattern. Those studies show that the 
replacement (infiltrative) pattern arises within the sinusoidal space and the pushing 
(nodular) pattern arises in the space of Disse. Our laboratory has found that mouse 
models of metastatic UM to the liver recapitulate the infiltrative and nodular growth 
patterns (unpublished data).  These models support the proposed mechanisms of 
metastatic UM growth in the liver, including NK control of the infiltrative pattern and 
PEDF control in the nodular pattern.28,33  
Recognition of the varying growth patterns of metastatic UM to the liver has 
clinical implications. For instance, the infiltrative and nodular growth patterns may be 
radiographically identified, with the nodular pattern being more amenable to 
chemoembolization and radioemboloization, as it is vascularized compared with the 
infiltrative pattern.34,35 MRI contrast agents are currently being developed that may 
enable detection of early stage infiltrative versus nodular growth patterns.36 Additionally, 
the choice of chemotherapeutic agents under development may be influenced by the 
infiltrative versus nodular growth patterns.37 
 In conclusion, we have shown that uveal melanoma metastasizes to the liver first 
in the form of single cells, followed by progressive stages. The single cell metastases 
10 
 
have cancer stem cell-like characteristics. These metastases result in the infiltrative and 
nodular growth patterns. We hypothesize that the following sequence of events is  
related to the formation of these two patterns.  In the infiltrative pattern, melanoma  
invades the sinusoidal space, replaces the hepatic lobule, is essentially avascular, and 
does not express VEGF. Hypoxia results in melanoma MMP production, the creation of 
pseudosinusoidal spaces, and tumor oxygenation. In the nodular growth pattern, 
melanoma arises in the periportal area,  co-opts the portal venule, and eventually 
grows, becomes hypoxic, expresses MMP9 and VEGF, undergoes angiogenesis, and 
effaces the adjacent hepatocytes. We propose that infiltrative growth is controlled in part 
by changes in the immune microenvironment in the sinusoidal space and nodular 
growth is controlled in part by the microenvironment VEGF:PEDF ratio in the periportal 
area. 
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Table 1. Histologic, IHC and IF Findings in Metastastic UM to the Liver 
  
  Infiltrative Pattern Nodular Pattern 
  
single 
cells 
Stage 
I 
Stage 
II 
Stage III 
single 
cells 
Stage 
I 
Stage 
II 
Stage III 
sinusoidal 
location 
+ + + + - - - - 
periportal 
location 
- - - - + + + + 
CD133+ 
melanoma 
+ few few - + few few - 
CD56+ NK cells + + few few - - - - 
CD3+ 
lymphocytes 
- - - - + + few few 
MMP9+ 
melanoma 
- - + - - - + +  
VEGF+ 
melanoma 
- - - - - - + + 
pseudo-
sinusoidal 
spaces 
- - + + - - - - 
angiogenesis - - - - - - - + 
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Figure legends. 
 
Figure 1.  Number of metastases per area of Stage I, II and III infiltrative and nodular 
metastases. In the infiltrative pattern, there was a significant decrease in numbers going 
from StageI to Stage III metastases. In the nodular growth pattern, there was 
approximately one metastases per 2 cm2 for all three stages. Standard deviations are 
shown. 
 
Figure 2. BAP1, CD56 and CD3 expression in melanocytes, NK cells and T 
lymphocytes. A. There is BAP1 expression (red) in a collection of metastatic UM cells in 
the liver. B. Collection of metastatic UM cells which are not expressing  BAP1. C. There 
are scattered CD56+ NK cells in the sinusoidal space. D. There are CD3+ cells in the 
periportal area which includes the bile duct (*) and portal venule (star).  
(A and B.  BAP1, peroxidase anti-peroxidase with vector red chromagen, 100X. C. 
CD56, peroxidase anti-peroxidase, 100X. D. CD3, peroxidase anti-peroxidase, 25X) 
 
Figure 3. Single cell infiltrative growth pattern. A. There are metastatic UM cells present 
in the sinusoidal spaces of the hepatic lobule. B. These single cells include lymphocytes 
and cells with slightly more eosinophilic cytoplasm. C. The cells with the slightly more 
cytoplasm express HMB45 (arrows). D. These cell express both HMB45 and CD133 
(orange).  
(A. H&E 25X, B. H&E 100X, C. HMB45, peroxidase anti-peroxidase with vector red 
chromagen, 100X, D. Dual labeling for HMB45 green chromagen and CD133 red 
chromagen, 100X).  
 
Figure 4. Stage 1 infiltrative growth pattern. A. The individual metastatic UM cells in the 
sinusoidal spaces are clumping and forming small clusters. B. These clusters of 
melanoma cells, or micrometastases, begin to expand the sinusoidal space. C. The 
micrometastatic melanoma expresses HMB45. D. Dual labeling for HMB45 (green) and 
CD 133 (red) show that most of the larger melanoma cells in the micrometastases 
express only HMB45 whereas small, individual melanoma cells express both HMB45 
and CD133 (orange).  
(A. H&E 25X, B. H&E 100X, C. HMB45, peroxidase anti-peroxidase with vector red 
chromagen, 100X, D. Dual labeling for HMB45 (green chromagen) and CD133 (red 
chromagen), 100X). 
 
Figure 5. Stage 2 infiltrative growth pattern. A. The sinusoidal spaces are filled with 
metastatic melanoma cells and the hepatocytes have been destroyed. B. The 
melanoma cells express HMB45. C. Dual labeling for HMB45 (green) and CD133 (red) 
show that there are many melanoma cells (green) and only rare small individual dual 
labeled melanoma cells (orange). D. These metastatic UM cells express MMPs (red) 
and no VEGF (green).  
(A. H&E 100X, B. HMB45, peroxidase-anti-peroxidase with vector red chromagen, 
100X, C. Dual labeling for HMB45 (green chromagen) and CD133 (red chromagen), 
100X D. Dual labeling for HMB45 (green chromagen) and MMP9 (red chromagen), 
100X). 
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Figure 6. Stage 3 infiltrative growth pattern. A. There is complete replacement of the 
hepatic lobule with islands of melanoma. B. The islands of melanoma express HMB45. 
C. Dual labeling for HMB45 (green) and CD133 (red) show a only HMB45 expression in 
the islands of melanoma, although there are rare, small dual labeled cells present. D. 
There is an absence of VEGF (green) express and MMP (red) expression by the 
melanoma cells.  
(A. H&E 25X, B. HMB45, peroxidase-anti-peroxidase with vector red chromagen, 25X,  
C. Dual labeling for HMB45 (green chromagen) and CD133 (red chromagen) 100X, D. 
Dual labeling for VEGF (green chromagen) and MMP (red chromagen), 100X).  
 
Figure 7. Single cell nodular growth pattern.  A. Rare individual mononuclear cells 
(arrow) with slightly more cytoplasm than lymphocytes are identified in fibrous tissue 
adjacent to the portal venule (*). B. A trichrome stain highlights the collagen within the 
portal triad which includes the portal venule (*). C. The rare mononuclear cells in this 
tissue express HMB45.  The portal venule is present (*) and there are scattered 
lymphocytes also present. D. There is dual labeling for HMB45 and CD133 (orange) in 
rare mononuclear cells in the periportal area (arrows) and within the portal venule (*).  
(A. H&E 100X, B. Masson trichrome 100X, C. HMB45 peroxidase anti-peroxidase 
vector red chromagen 100X, D. Dual labeling for HMB45 green chromagen and CD133 
red chromagen, 100X).  
 
Figure 8.  Stage 2 nodular growth pattern. A. A well-demarcated nodule of UM cells is 
present and effaces the surround hepatic lobules. A trichrome stain highlights the portal 
venule (arrow) within the center of the nodule. B. The melanoma cells in the nodule 
express HMB45 and surround the portal venule, thus effacing the surround hepatic 
lobules. C. Melanoma cells express HMB45 (green) and there are no cells that express 
CD133. D. Dual labeling of the UM cells for VEGF (green) and MMP (red) is seen.  
(A. Masson trichrome 10X, B. HMB45 with vector red chromagen, peroxidase anti-
peroxidase, 10X, D. HMB45 with green chromagen, CD133 with red chromagen, 10X, 
F. VEGF with green chromagen, MMP9 with red chromagen, 100X).  
 
Figure 9. Stage 3 nodular growth pattern. A. A nodule of pigmented melanoma cells 
effaces the adjacent hepatic lobules.  A trichrome stain highlights minimal fibrosis 
surrounding the nodule of melanoma. B. Vascular channels express CD31 in the nodule 
of melanoma (arrow) and immediately adjacent tissue (*). C. The melanoma expresses 
HMB45 (green) but not CD133 (red). D. The melanoma co-expresses VEGF (green) 
and MMP (red), resulting in an orange dual-labeling.  
(A. Masson trichrome 10X, B. CD31 peroxidase anti-peroxidase, 10X, C. HMB45 with 
green chromagen, CD133 with red chromagen, 10X, D. VEGF with green chromagen, 
MMP with red chromagen, 100X). 
 
Figure 10.  Schematic cartoon of metastatic UM to the liver. Melanoma arises in the 
choroid of the eye (A), extravasates into tumor blood vessels, and then travels via the 
systemic circulation as circulating melanoma cells with tumor stem cell-like properties 
(B), where it enters the liver as single cells. These single cells likely arise from hepatic 
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arterioles and seed the sinusoidal space causing the infiltrative pattern of growth, which 
progresses to Stage 1 (0-50μm) micrometastases, Stage 2 intermediate (51-500μm) 
metastases which are bathed by serum in the sinusoidal space, and eventually Stage 3 
(>501μm) metastases which replace the hepatic lobule, do not express MMP9/VEGF or 
display angiogenesis. Alternatively, circulating melanoma cells may enter the liver via 
the portal venule causing the nodular growth pattern, first as single cells, then Stage 1 
(0-50μm) micrometastases that co-opt the portal venule, then Stage 2 (51-500μm)  
intermediate metastases that begin to efface the adjacent hepatic lobule, and finally 
Stage 3 (>501μm) metastases which express MMP9/VEGF, display angiogenesis and 
further efface the adjacent hepatic lobule. 
 
Figure 11. Schematic cartoon of proposed mechanisms of infiltrative and nodular 
growth patterns of metastatic UM to the liver. UM cells with tumor stem cell-like 
properties extravasate from the primary ocular tumor and disseminate hematogenously 
to the liver. In the infiltrative growth pattern, these UM cells may metastasize to the 
sinusoidal spaces in the parenchyma of the hepatic lobule and grow from single 
melanoma cells to Stages I-III metastases. This infiltrative growth is related in part to a 
change in the immune microenvironment within the sinusoidal space, including 
downregulation of NK cells.26,32 Hypoxia results in MMP production in Stage II which 
allows for tissue dissection and creation of pseudosinusoidal spaces. Micrometastases 
receive their nutrition form blood in the sinusoidal space; larger metastases are bathed 
by blood in pseudosinusoidal spaces.8 In the nodular growth pattern, circulating UM 
cells metastasize to the periportal areas in the hepatic triad, co-opt the portal venules 
for nutrition, and progress from single UM cells to Stages I-III metastases. Hypoxia 
results in MMP production and VEGF expression. Nodular growth is related in part to 
MMP degradation of PEDF, increased VEGF expression by melanoma cells, an 
increased VEGF:PEDF ratio and angiogenesis. 
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